---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-009874"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:07:41.025897+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharmaceuticals prices public offering of 4.325M shares at $19, expects ~$88.5M net proceeds

## Summary
- Priced 4,325,000 shares of common stock at $19.00 per share; underwriters' option for additional 648,750 shares exercised in full.
- Net proceeds expected to be approximately $88.5 million after underwriting discounts and estimated offering expenses.
- Offering expected to close on or about February 2, 2024; proceeds to fund clinical pipeline development and working capital.
- Jefferies acted as sole book-runner; H.C. Wainwright & Co. and Oppenheimer & Co. as lead managers.

## SEC filing metadata
- accession: 0000950170-24-009874
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/0000950170-24-009874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/crbp-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-009874
- JSON: https://secwatch.observer/filing/0000950170-24-009874.json
- Plain text: https://secwatch.observer/filing/0000950170-24-009874.txt

## Key facts
- Material Agreements
  Corbus Pharmaceuticals Holdings, Inc. entered into Underwriting Agreement with Jefferies LLC valued at approximately $88.5 million (effective 2024-01-31).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC
  - Value: approximately $88.5 million
  - Effective: 2024-01-31
  source text: On January 31, 2024, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 4,325,000 shares (the “Base Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), at a price to the public of $19.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/0000950170-24-009874-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.